• 1
    Fournier C, Sureau C, Coste J, Ducos J, Pageaux G, Larrey D, Domergue J, et al. In vitro infection of adult normal human hepatocytes in primary culture by hepatitis C virus. J Gen Virol 1998; 79: 23672374.
  • 2
    Castet V, Fournier C, Soulier A, Brillet R, Coste J, Larrey D, Dhumeaux D, et al. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol 2002; 76: 81898199.
  • 3
    Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110113.
  • 4
    Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 2002; 76: 1300113014.
  • 5
    Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2001; 75: 85168523.
  • 6
    Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 2001; 75: 46144624.
  • 7
    Lohmann V, Korner F, Dobierzewska A, Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 2001; 75: 14371449.
  • 8
    Lohmann V, Hoffmann S, Herian U, Penin F, Bartenschlager R. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J Virol 2003; 77: 30073019.
  • 9
    Ali N, Tardif KD, Siddiqui A. Cell-free replication of the hepatitis C virus subgenomic replicon. J Virol 2002; 76: 1200112007.
  • 10
    Hardy RW, Marcotrigiano J, Blight KJ, Majors JE, Rice CM. Hepatitis C virus RNA synthesis in a cell-free system isolated from replicon-containing hepatoma cells. J Virol 2003; 77: 20292037.
  • 11
    Lai VC, Dempsey S, Lau JY, Hong Z, Zhong W. In vitro RNA replication directed by replicase complexes isolated from the subgenomic replicon cells of hepatitis C virus. J Virol 2003; 77: 22952300.
  • 12
    Lanford RE, Bigger C. Advances in model systems for hepatitis C virus research. Virology 2002; 293: 19.
  • 13
    Xie ZC, Riezu-Boj JI, Lasarte JJ, Guillen J, Su JH, Civeira MP, Prieto J. Transmission of hepatitis C virus infection to tree shrews. Virology 1998; 244: 513520.
  • 14
    Ilan E, Arazi J, Nussbaum O, Zauberman A, Eren R, Lubin I, Neville L, et al. The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV. J Infect Dis 2002; 185: 153161.
  • 15
    Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927933.
  • 16
    Lesko LJ, Rowland M, Peck CC, Blaschke TF. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res 2000; 17: 13351344.
  • 17
    Nebert DW, Russell DW. Clinical importance of the cytochrome P450. Lancet 2002; 360: 11551162.
  • 18
    Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov 2002; 1: 259266.
  • 19
    Wienkers LC. Factors confounding the successful extrapolation of in vitro CYP3A inhibition information to the in vivo condition. Eur J Pharm Sci 2002; 15: 239242.
  • 20
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103107.
  • 21
    Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, Perelson AS, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 2835.
  • 22
    Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, Colucci G, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120: 14381447.
  • 23
    Layden JE, Layden TJ, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat 2002; 9: 340345.
  • 24
    Bekkering FC, Brouwer JT, Hansen BE, Schalm SW. Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin. J Hepatol 2001; 34: 435440.
  • 25
    Bekkering FC, Brouwer JT, Leroux-Roels G, Van Vlierberghe H, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol 1998; 28: 960964.
  • 26
    Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. HEPATOLOGY 2001; 33: 419423.
  • 27
    Pawlotsky JM. Antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res 2003; 59: 111.
  • 28
    Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000; 283: 24172426.
  • 29
    Soler M, Penin F, Ray S, Dhumeaux D, Pawlotsky JM. Hepatitis C virus NS3 serine protease variability and evolution are strongly constrained by the need for structural and functional conservation. J Hepatol 2002; 36( suppl 1): 5.
  • 30
    Rijnbrand R, Bredenbeek PJ, Haasnoot PC, Kieft JS, Spaan WJ, Lemon SM. The influence of downstream protein-coding sequence on internal ribosome entry on hepatitis C virus and other flavivirus RNAs. RNA 2001; 7: 585597.
  • 31
    Yi M, Lemon SM. Structure-function analysis of the 3′ stem-loop of hepatitis C virus genomic RNA and its role in viral RNA replication. RNA 2003; 9: 331345.
  • 32
    Spahn CM, Kieft JS, Grassucci RA, Penczek PA, Zhou K, Doudna JA, Frank J. Hepatitis C virus IRES RNA-induced changes in the conformation of the 40s ribosomal subunit. Science 2001; 291: 19591962.
  • 33
    Kieft JS, Zhou K, Grech A, Jubin R, Doudna JA. Crystal structure of an RNA tertiary domain essential to HCV IRES-mediated translation initiation. Nat Struct Biol 2002; 9: 370374.
  • 34
    Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996; 87: 343355.
  • 35
    Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T, et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 1996; 87: 331342.
  • 36
    Bianchi E, Pessi A. Inhibiting viral proteases: challenges and opportunities. Biopolymers 2002; 66: 101114.
  • 37
    Fischmann TO, Weber PC. Peptidic inhibitors of the hepatitis C virus serine protease within non-structural protein 3. Curr Pharm Des 2002; 8: 25332540.
  • 38
    Borowski P, Schalinski S, Schmitz H. Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy. Antiviral Res 2002; 55: 397412.
  • 39
    Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure Fold Des 1999; 7: 13531363.
  • 40
    Caruthers JM, McKay DB. Helicase structure and mechanism. Curr Opin Struct Biol 2002; 12: 123133.
  • 41
    Ago H, Adachi T, Yoshida A, Yamamoto M, Habuka N, Yatsunami K, Miyano M. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure Fold Des 1999; 7: 14171426.
  • 42
    Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, De Francesco R, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci U S A 1999; 96: 1303413039.
  • 43
    Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 1999; 6: 937943.
  • 44
    Bressanelli S, Tomei L, Rey FA, De Francesco R. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J Virol 2002; 76: 34823492.
  • 45
    Wang M, Ng KK, Cherney MM, Chan L, Yannopoulos CG, Bedard J, Morin N, et al. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J Biol Chem 2003; 278: 94899495.
  • 46
    Flint M, Thomas JM, Maidens CM, Shotton C, Levy S, Barclay WS, McKeating JA. Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol 1999; 73: 67826790.
  • 47
    Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, et al. Binding of hepatitis C virus to CD81. Science 1998; 282: 938941.
  • 48
    Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21: 50175025.
  • 49
    Pohlmann S, Zhang J, Baribaud F, Chen Z, Leslie GJ, Lin G, Granelli-Piperno A, et al. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol 2003; 77: 40704080.
  • 50
    Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999; 96: 1276612771.
  • 51
    Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197: 633642.
  • 52
    Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, McKeating JA. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 2003; 100: 72717276.
  • 53
    Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, Govindarajan S, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A 2002; 99: 1566115668.
  • 54
    Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6: 578582.
  • 55
    Nascimbeni M, Mizukoshi E, Bosmann M, Major ME, Mihalik K, Rice CM, Feinstone SM, et al. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol 2003; 77: 47814793.
  • 56
    Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, Lanford RE. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. HEPATOLOGY 2001; 33: 14791487.
  • 57
    Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, McKinney D, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001; 15: 883895.
  • 58
    Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, Liang TJ, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002; 169: 34473458.
  • 59
    Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 2002; 123: 10701083.
  • 60
    Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 22472250.
  • 61
    Rockey DC. Hepatic fibrogenesis and hepatitis C. Semin Gastrointest Dis 2000; 11: 6983.
  • 62
    Friedman SL. Liver fibrosis—from bench to bedside. J Hepatol 2003; 38( suppl 1): S38S53.
  • 63
    Friedman SL. Hepatic stellate cells. Prog Liver Dis 1996; 14: 101130.
  • 64
    Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci U S A 1985; 82: 86818685.
  • 65
    Pestka S. The human interferon alpha species and receptors. Biopolymers 2000; 55: 254287.
  • 66
    Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997; 15: 563591.
  • 67
    Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 6368.
  • 68
    Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 1996; 16: 489499.
  • 69
    Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Hollinger FB, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. HEPATOLOGY 1997; 26: 747754.
  • 70
    Chang CC, Chen TT, Cox BW, Dawes GN, Stemmer WP, Punnonen J, Patten PA. Evolution of a cytokine using DNA family shuffling. Nat Biotechnol 1999; 17: 793797.
  • 71
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 72
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 73
    Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyanathan S, Green M, Baker DP, et al. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther 2001; 297: 10591066.
  • 74
    Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002; 303: 540548.
  • 75
    Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother 2001; 48: 751755.
  • 76
    Goldstein D, Hertzog P, Tomkinson E, Couldwell D, McCarville S, Parrish S, Cunningham P, et al. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J Infect Dis 1998; 178: 858861.
  • 77
    Strominger NL, Brady R, Gullikson G, Carpenter DO. Imiquimod-elicited emesis is mediated by the area postrema, but not by direct neuronal activation. Brain Res Bull 2001; 55: 445451.
  • 78
    Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. HEPATOLOGY 2002; 35: 10021009.
  • 79
    Watson J. Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives of ribavirin. Curr Opin Investig Drugs 2002; 3: 680683.
  • 80
    Wu JZ, Walker H, Lau JY, Hong Z. Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob Agents Chemother 2003; 47: 426431.
  • 81
    Sintchak MD, Nimmesgern E. The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 2000; 47: 163184.
  • 82
    Maxamine. Histamine dihydrochloride. Drugs R D 1999; 2: 274275.
  • 83
    Billich A. Thymosin alpha1. SciClone Pharmaceuticals. Curr Opin Investig Drugs 2002; 3: 698707.
  • 84
    McHutchison JG, Patel K. Future therapy of hepatitis C. HEPATOLOGY 2002; 36: S245S252.
  • 85
    Pockros PJ, Patel K, O'Brien C, Tong M, Smith C, Rustgi V, Carithers RL, et al. A randomized, double-blind, placebo-controlled, multicenter study of recombinant human interleukin-12 for the treatment of chronic hepatitis C virus infection in patients non-responsive to previous treatment with interferon-alfa with or without ribavirin. HEPATOLOGY 2003; 37: 13681374.
  • 86
    Hanecak R, Brown-Driver V, Fox MC, Azad RF, Furusako S, Nozaki C, Ford C, et al. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J Virol 1996; 70: 52035212.
  • 87
    Zhang H, Hanecak R, Brown-Driver V, Azad R, Conklin B, Fox MC, Anderson KP. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob Agents Chemother 1999; 43: 347353.
  • 88
    McHutchison JG, Pockros PJ, Patel K, Nyberg L, Yu RZ, Kwoh TJ, Dorr FA. A phase 1b dose escalation trial of ISIS 14803, an antisense inhibitor of HCV, in patients with chronic HCV: final report. HEPATOLOGY 2002; 36: 303A.
  • 89
    Gordon SC, Bacon BR, Jacobson IM, Shiffman MI, Afdhal NH, McHutchison JG, Kwoh TJ, et al. A phase II, 12-week study of ISIS 14803, an antisense inhibitor of HCV for the treatment of chronic hepatitis C. HEPATOLOGY 2002; 36: 362A.
  • 90
    Macejak DG, Jensen KL, Pavco PA, Phipps KM, Heinz BA, Colacino JM, Blatt LM. Enhanced antiviral effect in cell culture of type 1 interferon and ribozymes targeting HCV RNA. J Viral Hepat 2001; 8: 400405.
  • 91
    Hannon GJ. RNA interference. Nature 2002; 418: 244251.
  • 92
    Durantel D, Branza-Nichita N, Carrouee-Durantel S, Butters TD, Dwek RA, Zitzmann N. Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus. J Virol 2001; 75: 89878998.
  • 93
    Pavlovic D, Neville DCA, Argaud O, Blumberg B, Dwek RA, Fischer WB, Zitzmann N. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci U S A 2003; 100: 61046108.
  • 94
    De Francesco R, Rice CM. New therapies on the horizon for hepatitis C: are we close? Clin Liver Dis 2003; 7: 211242.
  • 95
    Lamarre D, Bailey M, Bolger G, Cameron D, Cartier M, Faucher AM, Goudreau N, et al. The discovery of BILN 2061. An orally bioavailable small molecule inhibitor of the HCV serine protease and a promising antiviral for the treatment of hepatitis C. HEPATOLOGY 2002; 36: 279A.
  • 96
    Benhamou Y, Hinrichsen H, Sentjens R, Reiser M, Manns MP, Forns X, Avendano C, et al. Safety, tolerability and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, with advanced liver fibrosis. HEPATOLOGY 2002; 36: 304A.
  • 97
    Hinrichsen H, Benhamou Y, Reiser M, Sentjens R, Wedemeyer H, Calleja JL, Forns X, et al. First report on the antiviral efficacy of BILN 2061, a novel oral serine protease inhibitor, in patients with chronic hepatitis C genotype 1. HEPATOLOGY 2002; 36: 379A.
  • 98
    Walker MP, Hong Z. HCV RNA-dependent RNA polymerase as a target for antiviral development. Curr Opin Pharmacol 2002; 2: 534540.
  • 99
    Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, Shapiro M, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 1994; 91: 77927796.
  • 100
    Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, Shimizu Y, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 1996; 93: 1539415399.
  • 101
    Krawczynski K, Fattom A, Culver D, Kamili S, Spelbring J, Basham L, Sapan C, et al. Passive transfer of anti-HCV in chronic and acute HCV infection in chimpanzees: trials of experimental immune treatment. HEPATOLOGY 1999; 30: 423A.
  • 102
    Krawczynski K, Fattom A, Spelbring J, Naso R, Sapan C, Purdy M, Basham L, et al. Early termination of HCV infection by passive anti-HCV transfer in experimentally infected chimpanzees. HEPATOLOGY 1998; 28: 398A.
  • 103
    Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, Walker B, et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001; 75: 55505558.
  • 104
    Depraetere S, Van Kerschaever E, Van Vlierberghe H, Elewaut A, Brouwer JT, Niesters HG, Schalm SW, et al. Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers. J Med Virol 2000; 60: 126132.
  • 105
    Baumert TF, Wellnitz S, Aono S, Satoi J, Herion D, Tilman Gerlach J, Pape GR, et al. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. HEPATOLOGY 2000; 32: 610617.
  • 106
    Leroux-Roels G, Depla E, Hulstaert F, De Smedt J, Desombere I, Maertens G. A candidate therapeutic vaccine for chronic hepatitis C infection based on envelope 1 protein: tolerability and immunogenicity in healthy adult volunteers. HEPATOLOGY 2000; 34: 449A.